EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes



Serum erythropoietin level and marrow erythroid infiltration predict response to recombinant human erythropoietin in myelodysplastic syndromes



Haematologica 78(2): 118-122



Background and methods: In 38 patients with myelodysplastic syndromes (MDS) the values of serum erythropoietin were measured at diagnosis and compared with the haemogloblin level. A highly significant inverse relationship was found between these two parameters, suggesting that the physiologic mechanism of erythroid progenitor cell recruitment is preserved in MDS. Fourteen transfusion-dependent patients were treated with recombinant human erythroproietin at the dose of 150 U/Kg three times weekly for at least 2 months. Results and conclusions: Under recombinant human erythropoietin, three patients became transfusion-independent and 5 had a transient decrease of their transfusion requirement. Two patients under prolonged treatment at the same dose of erythropoietin remain in complete remission after 12 and 15 months respectively. A direct relationship between response to erythropoietin treatment and degree of bone marrow erythroid hyperplasia, coupled to an inverse correlation between response to erythropoietin and baseline serum erythropoietin levels were noted. Based on these findings, recombinant human erythropoietin may represent an effective treatment modality for selected patients with MDS.

(PDF emailed within 1 workday: $29.90)

Accession: 009405199

Download citation: RISBibTeXText

PMID: 8349187



Related references

Prolonged administration of erythropoietin or erythropoietin and granulocyte colony-stimulating factor increases erythroid response rate in patients with myelodysplastic syndromes. Leukemia Research 25(Supplement 1): S73, June, 2001

Serum levels of tumour necrosis factor-alpha predict response to recombinant human erythropoietin in patients with myelodysplastic syndrome. Clinical and Laboratory Haematology 19(3): 197-201, 1997

Does the adjunct of G-CSF, GM-CSF or IL-3 significantly improve in vivo erythroid response in myelodysplastic syndromes unresponsive to recombinant erythropoietin alone? A single center study of 40 patients. Blood 92(10 SUPPL 1 PART 1-2): 421A, Nov 15, 1998

Response to recombinant human erythropoietin treatment in myelodysplastic syndromes (MDS). Journal of Internal Medicine 229(4): 381-382, 1991

Endogenous erythropoietin level does not predict response to recombinant erythropoietin in ESRD patients with AIDS. Journal of the American Society of Nephrology 13(Program and Abstracts Issue): 417A, September, 2002

Recombinant human erythropoietin in the treatment of myelodysplastic syndromes--response patterns. Leukemia & Lymphoma 15(1-2): 149-152, 1994

Prediction of response to treatment with human recombinant erythropoietin in myelodysplastic syndromes. Leukemia 7(9): 1324-1327, 1993

Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. European Journal of Haematology 68(3): 180-186, 2002

Treatment with mycophenolate mofetil followed by recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes resistant to erythropoietin treatment. Haematologica 95(2): 339-340, 2010

Evaluation of erythroid marrow response to recombinant human erythropoietin in patients with cancer anaemia. Haematologica 77(6): 494-501, 1992

The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis. Experimental Hematology 19(7): 613-616, 1991

Comparative analysis of the effects of the unpurified preparations of murine erythropoietin and human recombinant erythropoietin on erythroid and granulocyte-macrophage progenitor cells in semi-solid mouse bone marrow cultures. Biulleten' Eksperimental'noi Biologii i Meditsiny 112(8): 176-179, 1991

Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood 99(5): 1578-1584, 2002

Response to recombinant human erythropoietin and granulocyte macrophage colony-stimulating factor in patients with low-risk myelodysplastic syndromes. Blood 90(10 SUPPL 1 PART 1): 84A, Nov 15, 1997

Sustained resolution of anemia without any treatment after excessive therapeutic response to human recombinant erythropoietin in three patients with myelodysplastic syndromes. Supportive Care in Cancer 21(7): 1803-1805, 2014